Trial Information

Summary: Cetuximab at Either 500 or 750mg/m2 Every Other Week for Platinum Refractory Cancer of the Head and Neck

You have been asked to participate in this research study because you have squamous cell cancer of the head and neck (SCCHN), your disease has grown after being treated with a platinum-based chemotherapy drug or you are felt not to be a candidate for platinum-based treatment. The purpose of this study is to determine how well subjects respond and how well the disease is controlled with the two different doses of Cetuximab. The safety and tolerability of Cetuximab given at the standard dose will also be determined. Your treatment on this study will last until your disease progresses or your treating physician determines that this study is no longer the best treatment for you. After your treatment is over, your medical condition will continue to be followed every 3 months for the rest of your life.

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: October 6, 2008 at 3:00:53 PM